These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36544653)

  • 1. The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review.
    Wang X; Hu S; Su F; Lin J; Duan J; Tan H; Tan H
    Ann Transl Med; 2022 Nov; 10(22):1254. PubMed ID: 36544653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
    Zhang P; Shi S; Xu J; Chen Z; Song L; Zhang X; Cheng Y; Zhang Y; Ye F; Li Z; Yin F; Ji D; Gao H; Li Y; Chen W; Yang M; Weng D; Wu C; Ma Y; Sheng W; Zhao Y; Yin X; Shen W; Su W; Shi M; Fan S; Tan P; Xu Q; Lu M; Shen L
    Eur J Cancer; 2024 Mar; 199():113539. PubMed ID: 38237373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Metastatic refractory undifferentiated small round-cell sarcoma successfully treated with surufatinib and camrelizumab.
    Li Y; Huang J; Chen X; Ye Y; Du X; Voutsadakis IA; Seetharam M; Zhang H; Lu M
    Front Oncol; 2024; 14():1416241. PubMed ID: 39055564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.
    Kamboj M; Gandhi JS; Gupta G; Sharma A; Pasricha S; Mehta A; Chandragouda D; Sinha R
    J Gastrointest Cancer; 2015 Dec; 46(4):356-64. PubMed ID: 26208508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to hepatic arterial infusion chemotherapy combined with camrelizumab and targeted therapy in advanced primary hepatic neuroendocrine carcinoma: a case report and literature review.
    Shi X; Su Z; Liang Z; Sun X; Luo J; Long Z; Jiang H; Strosberg J; Paluri RK; Xiao Y
    J Gastrointest Oncol; 2024 Aug; 15(4):1962-1972. PubMed ID: 39279984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
    Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
    Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
    Liu L; Liu Y; Gong L; Zhang M; Wu W
    Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC).
    Mohamed A; Vijayvergia N; Kurian M; Liu L; Fu P; Das S
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681675
    [No Abstract]   [Full Text] [Related]  

  • 9. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
    Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
    Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.
    Yoon SE; Kim JH; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
    J Cancer; 2019; 10(14):3140-3144. PubMed ID: 31289584
    [No Abstract]   [Full Text] [Related]  

  • 12. S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report.
    Wang X; Shi YF; Duan JH; Wang C; Tan HY
    World J Clin Cases; 2021 Aug; 9(24):7146-7153. PubMed ID: 34540971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies.
    Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
    ESMO Open; 2022 Apr; 7(2):100453. PubMed ID: 35344750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of small cell neuroendocrine carcinoma of gallbladder origin.
    Dülger UC; Erdem Ş; Cünük ES; Altıntoprak F
    J Surg Case Rep; 2024 Jun; 2024(6):rjae386. PubMed ID: 38832057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of colorectal large cell neuroendocrine carcinoma accompanied by disseminated peritoneal leiomyomatosis.
    Suga K; Ogawa H; Sohda M; Katayama C; Ozawa N; Osone K; Okada T; Shiraishi T; Katoh R; Sano A; Sakai M; Yokobori T; Shirabe K; Saeki H
    Surg Case Rep; 2020 Dec; 6(1):316. PubMed ID: 33296060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
    Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas.
    Gile JJ; McGarrah PW; Leventakos K; Sonbol MB; Starr JS; Eiring RA; Hobday TJ; Halfdanarson TR
    J Neuroendocrinol; 2023 May; 35(5):e13283. PubMed ID: 37229903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of first-line chemotherapy based on primary site of tumor versus etoposide-platinum in advanced gastroenteropancreatic neuroendocrine carcinoma.
    Shen H; Gu Y; Fang Y; Xu T; Xu Y; Wu X; Shu Y; Ma P
    J Gastrointest Oncol; 2024 Jun; 15(3):921-930. PubMed ID: 38989422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.
    Terashima T; Morizane C; Hiraoka N; Tsuda H; Tamura T; Shimada Y; Kaneko S; Kushima R; Ueno H; Kondo S; Ikeda M; Okusaka T
    Neuroendocrinology; 2012; 96(4):324-32. PubMed ID: 22572060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?
    Frizziero M; Durand A; Taboada RG; Zaninotto E; Luchini C; Chakrabarty B; Hervieu V; Claro LCL; Zhou C; Cingarlini S; Milella M; Walter T; Riechelmann RS; Lamarca A; Hubner RA; Mansoor W; Valle JW; McNamara MG
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.